Ep4: Richard Pops

Episode Summary

Executive Summary: Luke Timmerman interviews Alkermes CEO Richard Pops about Vivitrol, the company’s monthly injectable naltrexone for opioid dependence. Pops argues addiction is a chronic, stigmatized disease best treated with multiple options, counseling, and systems of care—not a single silver bullet. He defends Alkermes’ pricing, marketing, and policy work while emphasizing the public health scale of the crisis and the need for broader access to medication-assisted treatment.

Main Topics: Vivitrol’s mechanism and role in addiction treatment (Priority: 5/5): Pops explains that Vivitrol is a once-monthly opioid receptor antagonist that blocks the high from opioids and is intended to prevent relapse after detoxification. Why Alkermes entered addiction medicine (Priority: 4/5): The company leveraged long-acting injectable technology developed in schizophrenia to address alcohol and opioid dependence, aiming at large, underserved diseases. The opioid epidemic as a public health emergency (Priority: 5/5): The conversation frames opioid addiction as a massive, worsening national crisis that has killed tens of thousands and overwhelms healthcare and criminal justice systems. Competition with Suboxone and the treatment ecosystem (Priority: 5/5): Pops argues methadone, buprenorphine/Suboxone, and Vivitrol serve different patient needs and that treatment access is often determined by where a patient enters the system. Marketing, political criticism, and access to care (Priority: 4/5): The episode addresses media criticism that Alkermes over-markets Vivitrol or influences policy. Pops says the company is responding to unmet need and advocating for patient-centered access to all approved therapies. Need for integrated care beyond medication (Priority: 5/5): Both host and guest stress that medication must be paired with detox, counseling, care coordination, and social support to improve outcomes and reduce relapse. Broader implications for serious mental illness (Priority: 3/5): Pops uses addiction as a model for Alkermes’ larger mission in serious mental illness, arguing long-acting, adherence-supporting therapies and systems reform are broadly needed.

Key Arguments: Addiction should be treated as a chronic disease with multiple valid therapies; no single medication fits all patients. Vivitrol fills a gap because it offers opioid blockade for patients who want to be detoxed and avoid relapse rather than remain on agonist replacement therapy. Long-acting injectables improve adherence and outcomes by removing the daily decision point that fuels relapse. The opioid epidemic was created by overprescribing and requires prevention, treatment access, and policy reform—not just new drugs. Alkermes’ advocacy is aimed at expanding access to all FDA-approved medications, not suppressing competitors. Criticism of Vivitrol’s marketing and policy engagement is, in Pops’s view, often factually wrong and ignores patient demand. Most real-world success depends on wraparound services like counseling, care coordination, jobs, and stable housing, not medication alone. The treatment system is broken because only about 10% of people with opioid addiction receive medication-assisted treatment. The company sees Vivitrol as a life-saving, cost-effective option relative to many high-priced therapies in other fields. The proper evaluation metric is patient-centered outcomes in local settings—recidivism, ER use, health utilization—not abstract comparisons alone.

Data Points: Vivitrol sales in Q2: $66 million - Alkermes reported sales for the quarter ended June 30. Vivitrol growth: 40% - Year-over-year growth in the second quarter. Company valuation: about $8 billion - Approximate market value of Alkermes. Opioid overdose deaths: 60,000 per year - Pops cites annual U.S. deaths from opioid overdose. Approved medicines for opioid dependence at the time: 3 - Methadone, Suboxone/buprenorphine, and long-acting naltrexone/Vivitrol. Treatment penetration: 10% - Approximate share of people with opioid addiction receiving medication-assisted treatment. Patients in the Norway randomized study: 159 - Head-to-head study of Vivitrol vs. standard care/Suboxone referenced in JAMA Psychiatry. Opioid prescriptions and overdose/addiction trend: quadrupled from 1999 to 2015 - Referenced from a commission report describing epidemic growth. Vivitrol list price: $1,300 per month - Pops states the list price for the medication. Vivitrol commercial payer price: around $900 per month - Approximate price paid by most commercial payers. Vivitrol Medicaid price: $500 to $600 per month - Approximate price range for Medicaid coverage. Suboxone medicine cost: $300 to $500 - Pops gives a rough medicine-only price comparison. Vivitrol market share: 3% - Pops says Vivitrol has a small but growing share of the treatment market. Vivitrol sales target: over $200 million this year - Projected annual sales at the time of the interview. Pilot programs: over 500 in 40 states - Programs measuring outcomes and adoption of Vivitrol around the country.

Pivotal Quotes: "60,000 people will die this year from opioid overdose deaths in the U.S." — Richard Pops: He uses this to underscore the scale and urgency of the opioid crisis. "If you think of the brain, picture in your mind what a human brain looks like in that big outer cortex... Our drug is affecting in the reptilian part of the brain." — Richard Pops: He explains the biological and behavioral distinction between craving and recovery. "All patients should have access to all medications." — Richard Pops: He summarizes Alkermes’ policy stance on opioid addiction treatment options.

Implications: The episode argues that addiction treatment should be broader, more evidence-based, and more coordinated. For industry, it suggests value in patient-centered systems, not just drug sales; for listeners, it highlights how medication, counseling, and policy must work together to reduce relapse and deaths.